Guardant Health (NASDAQ: GH) previews 2025 results, JPM conference

Rhea-AI Filing Summary

Guardant Health, Inc. reported that on January 11, 2026 it announced certain preliminary unaudited financial information for the quarter and full year ended December 31, 2025. This information is provided in a press release that is furnished as Exhibit 99.1 to the report, rather than being formally filed, which limits how it is incorporated into other regulatory documents.

The company also disclosed that it will post the investor presentation used at the 2026 J.P. Morgan Healthcare Conference, scheduled for January 12, 2026, on its website under the Investors section. These updates are intended to give the market an early view of recent performance and the materials being shared with investors.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001576280false00015762802026-01-112026-01-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 11, 2026

GUARDANT HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38683

45-4139254

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

3100 Hanover Street

Palo Alto, California 94304

(Address of principal executive offices) (Zip Code)

855-698-8887

(Registrant’s telephone number, include area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.00001 par value per share			GH			The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02. Results of Operations and Financial Conditions.

On January 11, 2026, Guardant Health, Inc. (the “Company”) announced certain preliminary unaudited financial information for the quarter and full year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01. Regulation FD Disclosure.

The Company will post the presentation that it will present at the 2026 J.P. Morgan Healthcare Conference on January 12, 2026 to the Company’s website, www.guardanthealth.com, on the “Events & Presentations” page under the “Investors” tab.

The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press Release of Guardant Health, Inc., dated January 11, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						GUARDANT HEALTH, INC.
Date:			January 12, 2026			By:			/s/ Michael Bell
									Michael Bell
									Chief Financial Officer
									(Principal Accounting Officer and Principal Financial Officer)

FAQ

What did Guardant Health (GH) disclose in this 8-K filing?

Guardant Health disclosed that it announced certain preliminary unaudited financial information for the quarter and full year ended December 31, 2025, and furnished the related press release as Exhibit 99.1.

Which period does Guardant Health’s preliminary financial information cover?

The preliminary unaudited financial information covers the quarter and full year ended December 31, 2025.

How can investors access Guardant Health’s preliminary 2025 results details?

Investors can review the details in the press release furnished as Exhibit 99.1 to the report, which contains the preliminary unaudited financial information.

What did Guardant Health say about the J.P. Morgan Healthcare Conference?

Guardant Health stated it will post the presentation used at the 2026 J.P. Morgan Healthcare Conference on January 12, 2026 on its website under the Investors "Events & Presentations" page.

Is the preliminary financial information considered filed with the SEC?

No. The company specified that the information furnished in this report, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Exchange Act or automatically incorporated into other filings.

Who signed the Guardant Health 8-K covering the preliminary results?

The report was signed on behalf of Guardant Health, Inc. by Michael Bell, Chief Financial Officer, who is also the principal accounting officer and principal financial officer.